AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Journey Medical CEO to speak at investor conferences in September 2025.
ByAinvest
Wednesday, Sep 3, 2025 8:36 am ET1min read
Journey Medical Corporation announced that Claude Maraoui, CEO, will participate in two investor conferences in September 2025. Maraoui will participate in a fireside chat and 1x1 meetings at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 and at the Lake Street Capital Markets 9th Annual Best Ideas Growth (BIG9) Conference on September 11. Journey Medical is a commercial-stage pharmaceutical company focused on dermatological conditions.
Journey Medical Corporation (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on dermatological conditions, has announced that Claude Maraoui, Co-Founder, President, and Chief Executive Officer, will participate in two September 2025 investor conferences. Maraoui will engage in a fireside chat and 1x1 meetings at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, and at the Lake Street Capital Markets 9th Annual Best Ideas Growth (BIG9) Conference on September 11, both in New York City.Journey Medical markets eight branded FDA-approved prescription drugs for treating common skin conditions. The company, located in Scottsdale, Arizona, was founded by Fortress Biotech, Inc. (Nasdaq: FBIO) and is known for its efficient sales and marketing model. The company's products include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend, as well as two authorized generic products, sulconazole nitrate cream and solution, and doxycycline hyclate immediate release 50mg tablets.
The participation in these conferences is an opportunity for investors and financial professionals to gain insights into the company's strategies, market position, and future growth prospects. Maraoui's involvement underscores Journey Medical's commitment to transparency and engagement with its stakeholders.
References:
[1] https://www.globenewswire.com/news-release/2025/09/03/3143630/0/en/Journey-Medical-Corporation-to-Participate-in-September-2025-Investor-Conferences.html
[2] https://www.stocktitan.net/news/DERM/journey-medical-corporation-to-participate-in-september-2025-elhqiebx3t5p.html
[3] https://ir.journeymedicalcorp.com/new-events/press-releases/detail/95/journey-medical-corporation-to-participate-in-september
[4] https://www.marketscreener.com/news/journey-medical-corp-may-sell-3-750-000-shares-of-common-stock-ce7c50dcda8df121
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet